| Name | Title | Contact Details |
|---|---|---|
Pat Higgins |
Senior Director, Global Alliance Management & Commercial Counsel | Profile |
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
At Karuna, our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions. Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don`t come easy, but are borne from passion and hard work. Together, we are working toward a goal bigger than ourselves.
Farmaceutical is a licensed medical marijuana business located in Pennsylvania and Ohio.
Cardeas BPU™ (Biosignal Processing Unit) is a biocompatible semiconductor capable of translating real-time streams of multiomics signals to digital information
Becton Dickinson & Company is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.